Lee K A, O'Sullivan C, Daly P, Pears J, Owens C, Timmermann B, Ares C, Combs S E, Indelicato D, Capra M
St. Luke's Radiation Oncology Network, Radiation Oncology, Dublin, Ireland.
Our Lady's Children's Hospital Crumlin, Paediatic Oncology, Dublin, Ireland.
Ir J Med Sci. 2017 Aug;186(3):577-582. doi: 10.1007/s11845-016-1520-9. Epub 2016 Oct 15.
Proton therapy (PT) is a radiotherapy treatment modality that uses protons, rather than conventional photons. PT is often used in paediatric oncology due to its reported capability to reduce acute and late adverse treatment effects. As PT is unavailable in Ireland, patients are referred abroad for treatment.
To: (1) produce a descriptive study of Irish children referred abroad for PT, and (2) discuss the case for PT in general.
A retrospective review of all children referred for PT before October 2015 was performed. Information was gathered regarding demographics, diagnosis, referral timeline, adverse effects attributable to PT, current status and cost. A review of the relevant literature was performed.
Seventeen children treated in Ireland have been referred abroad for PT. The largest number was in the 0-4 year old group. At initial diagnosis the median age was 4.8 years. The average cost per child was €37,312. Two patients suffered disease relapse. Four have encountered PT-related adverse effects.
Despite the fact that >100,000 patients worldwide have been treated with PT, the level of published evidence to support superiority over conventional treatment remains low. It is debated that randomised control trials in this area would be inconsistent with the principle of clinical equipoise. In contrast, there is a call for level 1 evidence to justify drastic changes in patient care, particularly in light of recent reports of unexpected toxicities. In time, careful evaluation, follow-up and clinical trials will likely support the preferential use of PT in children.
质子治疗(PT)是一种放射治疗方式,它使用质子而非传统光子。由于据报道质子治疗能够减少急性和晚期不良治疗效果,因此常用于儿科肿瘤学。由于爱尔兰无法提供质子治疗,患者被转诊至国外接受治疗。
(1)对转诊至国外接受质子治疗的爱尔兰儿童进行描述性研究,(2)总体讨论质子治疗的情况。
对2015年10月前转诊接受质子治疗的所有儿童进行回顾性研究。收集了有关人口统计学、诊断、转诊时间线、质子治疗所致不良反应、当前状况和费用的信息。对相关文献进行了综述。
在爱尔兰接受治疗的17名儿童已被转诊至国外接受质子治疗。人数最多的是0至4岁年龄组。初诊时的中位年龄为4.8岁。每个儿童的平均费用为37312欧元。两名患者疾病复发。四名患者出现了与质子治疗相关的不良反应。
尽管全球已有超过100000名患者接受了质子治疗,但支持其优于传统治疗的已发表证据水平仍然较低。有人认为该领域的随机对照试验将不符合临床 equipoise原则。相比之下,有人呼吁提供一级证据,以证明患者护理方面的巨大变化是合理的,特别是鉴于最近有关意外毒性的报告。随着时间的推移,仔细的评估、随访和临床试验可能会支持在儿童中优先使用质子治疗。